Clinical trials on Eosinophilic asthma

Eosinophilic Asthma: An Overview

Eosinophilic asthma is a subtype of asthma characterized by a high level of eosinophils, a type of white blood cell, in the lungs and bloodstream. This condition is often more severe than other types of asthma and can be resistant to traditional asthma treatments. Patients with eosinophilic asthma may experience frequent exacerbations, leading to a significant impact on their quality of life. The exact cause of eosinophilic asthma is not fully understood, but it is believed to involve a complex interplay of genetic, environmental, and immunological factors.

Key Characteristics and Treatment

  • Diagnosis: Eosinophilic asthma is diagnosed through a combination of patient history, physical examination, and specific tests, including blood tests, sputum tests, and sometimes bronchial biopsies, to measure the level of eosinophils.
  • Treatment: Treatment for eosinophilic asthma often involves higher doses of inhaled corticosteroids and may include biological medications specifically designed to target eosinophils. These biologic therapies have been a breakthrough for many patients, offering improved control of symptoms and a reduction in asthma exacerbations.
  • Lifestyle and Management: Alongside medication, lifestyle changes such as avoiding asthma triggers, regular exercise, and maintaining a healthy weight can help manage symptoms. It’s also crucial for patients to work closely with their healthcare provider to monitor their condition and adjust treatment as necessary.

In conclusion, eosinophilic asthma represents a challenging and distinct form of asthma that requires specialized care and management. With the advent of targeted biological therapies, there is new hope for patients suffering from this condition, enabling them to lead more active and fulfilling lives.

  • CT-EU-00034282

    Benralizumab’s impact on severe asthma study

    The study will examine the effects of a drug called benralizumab on people suffering from a severe type of asthma called eosinophilic asthma. Scientists will do this by using special imaging technology called functional airway imaging (FRI) to take pictures of the lungs before and after treatment. It’s an open-label trial, which means everyone knows that the asthma drug under investigation is benralizumab. The study will last from 15 to 23 weeks. Participants in this study must be adults (18 years of age or older), both men and women, who already have severe eosinophilic asthma. Their asthma is not currently well treated with regular inhalers or other asthma medications. One of the goals of the study is to see if benralizumab helps reduce airway resistance and clear mucus in the lungs. Scientists will measure parameters such as lung volume, airway resistance and mucus accumulation.

    • Benralizumab
  • Study of the safety and effectiveness of benralizumab in the treatment of asthma in children

    This study examines benralizumab, a potential asthma treatment for children aged 6-18 with severe eosinophilic asthma. Participants, receiving high-dose inhaled corticosteroids and additional medication, are randomly assigned to receive either benralizumab or a placebo without knowing which. The goal is to assess the drug’s effectiveness in reducing asthma exacerbations and improving overall asthma control. Following the initial phase, all participants will receive benralizumab in an open-label extension, monitoring safety and response.

    • Benralizumab